← Back to Search

Anti-metabolites

Capecitabine + Neratinib for Breast Cancer

Phase 1 & 2
Waitlist Available
Led By Chau Dang, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) status of 0 to 1
Histologically confirmed MBC, current stage IV
Must not have
QTc interval >450 ms for men or 470 ms for women, or known history of QTc prolongation or Torsades de Pointes
Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association functional classification of ≥2), unstable angina, myocardial infarction within 12 months of enrollment, or ventricular arrhythmia
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing the safety of combining two drugs, neratinib and capecitabine, in a new dosing schedule for patients with advanced breast cancer. The goal is to find out if this new schedule is safer and more effective. Neratinib blocks proteins that help cancer grow, and capecitabine stops cancer cells from multiplying.

Who is the study for?
This trial is for adults with stage IV HER2-positive metastatic breast cancer who've had trastuzumab-based therapy. They can have up to four prior chemo treatments in the metastatic setting but not neratinib with capecitabine. Stable brain lesions are okay, and they must have a good heart function (LVEF ≥50%) and be able to perform daily activities (ECOG 0-1). Women must use effective contraception.
What is being tested?
The study tests the safety of neratinib combined with capecitabine at different doses in patients with advanced breast cancer. Capecitabine is FDA-approved; neratinib isn't yet approved for this use. The focus is on whether changing the dosing schedule can improve safety compared to standard schedules.
What are the potential side effects?
Potential side effects include diarrhea, liver issues, blood cell count changes, fatigue, nausea, hand-foot syndrome from capecitabine, and possible heart problems or severe allergic reactions due to neratinib.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can carry out all my daily activities without help.
Select...
My breast cancer is confirmed to be at stage IV.
Select...
My cancer shows high levels of HER2.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My heart's electrical cycle is longer than normal or I've had specific heart rhythm issues.
Select...
I do not have any severe heart conditions or recent heart attacks.
Select...
I've had high doses of specific chemotherapy drugs.
Select...
I had radiation therapy less than 14 days before starting the trial treatment.
Select...
I have a long-term stomach or bowel problem that causes serious diarrhea.
Select...
I have a known deficiency in the enzyme dihydropyrimidine dehydrogenase.
Select...
I am allergic to 5-fluorouracil or similar drugs.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Maximum Tolerated Dose (MTD)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: capecitabine 7/7 with neratinibExperimental Treatment3 Interventions
In the phase I portion of the study, a 3+3 design will be used. Once the MTD is reached, the phase II portion will enroll up to 24 patients. Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Patients will be seen on Day 1 of each cycle (+/- 3 days). The MD has been determined as 240mg of neratinib and 1000mg BID of capecitabine.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Capecitabine
2013
Completed Phase 3
~4280
Neratinib
2014
Completed Phase 2
~1970

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Neratinib is a tyrosine kinase inhibitor that targets the HER2 receptor, disrupting cell signaling pathways that promote cancer cell growth and survival. Capecitabine is a chemotherapy drug that inhibits DNA synthesis, leading to cancer cell death. These mechanisms are important for breast cancer patients as they help in selecting targeted therapies that can effectively manage their specific type of cancer, potentially improving outcomes and reducing side effects.
The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer.Neratinib for the treatment of breast cancer.Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report.

Find a Location

Who is running the clinical trial?

Puma Biotechnology, Inc.Industry Sponsor
57 Previous Clinical Trials
10,058 Total Patients Enrolled
13 Trials studying Breast Cancer
4,317 Patients Enrolled for Breast Cancer
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,979 Previous Clinical Trials
599,804 Total Patients Enrolled
207 Trials studying Breast Cancer
82,929 Patients Enrolled for Breast Cancer
Chau Dang, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
5 Previous Clinical Trials
243 Total Patients Enrolled
3 Trials studying Breast Cancer
178 Patients Enrolled for Breast Cancer

Media Library

Capecitabine (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT03377387 — Phase 1 & 2
Breast Cancer Research Study Groups: capecitabine 7/7 with neratinib
Breast Cancer Clinical Trial 2023: Capecitabine Highlights & Side Effects. Trial Name: NCT03377387 — Phase 1 & 2
Capecitabine (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03377387 — Phase 1 & 2
~4 spots leftby Dec 2025